B-cell function in CNS inflammatory demyelinating disease: a complexity of roles and a wealth of possibilities

References

• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med.343(13), 938–952 (2000).
   PubMed Web of Science ®Google Scholar
• Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol.47(6), 707–717 (2000).
   PubMed Web of Science ®Google Scholar
• Zamvil S, Nelson P, Trotter J et al. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature317(6035), 355–358 (1985).
   PubMed Web of Science ®Google Scholar
• Blennow K, Fredman P, Wallin A et al. Formulas for the quantitation of intrathecal IgG production. Their validity in the presence of blood–brain barrier damage and their utility in multiple sclerosis. J. Neurol. Sci.121(1), 90–96 (1994).
   PubMedGoogle Scholar
• Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult. Scler.4(3), 111–117 (1998).
   PubMed Web of Science ®Google Scholar
• Correale J, de los Milagros Bassani Molinas M. Oligoclonal bands and antibody responses in multiple sclerosis. J. Neurol.249(4), 375–389 (2002).
   PubMed Web of Science ®Google Scholar
• Lee KH, Hashimoto SA, Hooge JP et al. Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology41(5), 657–660 (1991).
   PubMed Web of Science ®Google Scholar
• Berger T, Rubner P, Schautzer F et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. Med.349(2), 139–145 (2003).
   PubMed Web of Science ®Google Scholar
• Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med.346(3), 158–164 (2002).
   PubMed Web of Science ®Google Scholar
• Thompson EJ, Kaufmann P, Rudge P. Sequential changes in oligoclonal patterns during the course of multiple sclerosis. J. Neurol. Neurosurg. Psychiatr.46(6), 547–550 (1983).
   PubMedGoogle Scholar
• Tourtellotte WW, Ma BI. Multiple sclerosis: the blood–brain-barrier and the measurement of de novo central nervous system IgG synthesis. Neurology28(9 Pt 2), 76–83 (1978).
   PubMedGoogle Scholar
• Walsh MJ, Tourtellotte WW, Roman J, Dreyer W. Immunoglobulin G, A, and M – clonal restriction in multiple sclerosis cerebrospinal fluid and serum – analysis by two-dimensional electrophoresis. Clin. Immunol. Immunopathol.35(3), 313–327 (1985).
   PubMedGoogle Scholar
• Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med.199(7), 971–979 (2004).
   PubMed Web of Science ®Google Scholar
• Astier AL, Meiffren G, Freeman S, Hafler DA. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J. Clin. Invest.116(12), 3252–3257 (2006).
   PubMed Web of Science ®Google Scholar
• Cruz M, Olsson T, Ernerudh J, Hojeberg B, Link H. Immunoblot detection of oligoclonal anti-myelin basic protein IgG antibodies in cerebrospinal fluid in multiple sclerosis. Neurology37(9), 1515–1519 (1987).
   PubMed Web of Science ®Google Scholar
• Garbay B, Heape AM, Sargueil F, Cassagne C. Myelin synthesis in the peripheral nervous system. Prog. Neurobiol.61(3), 267–304 (2000).
   PubMed Web of Science ®Google Scholar
• Stoffel W, Hillen H, Giersiefen H. Structure and molecular arrangement of proteolipid protein of central nervous system myelin. Proc. Natl Acad. Sci. USA81(16), 5012–5016 (1984).
   PubMedGoogle Scholar
• Omlin FX, Webster HD, Palkovits CG, Cohen SR. Immunocytochemical localization of basic protein in major dense line regions of central and peripheral myelin. J. Cell Biol.95(1), 242–248 (1982).
   PubMedGoogle Scholar
• Roach A, Takahashi N, Pravtcheva D, Ruddle F, Hood L. Chromosomal mapping of mouse myelin basic protein gene and structure and transcription of the partially deleted gene in shiverer mutant mice. Cell42(1), 149–155 (1985).
   PubMedGoogle Scholar
• Sprinkle TJ. 2´,3´-cyclic nucleotide 3´-phosphodiesterase, an oligodendrocyte-Schwann cell and myelin-associated enzyme of the nervous system. Crit. Rev. Neurobiol.4(3), 235–301 (1989).
   PubMedGoogle Scholar
• Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein. J. Neurochem.72(1), 1–9 (1999).
   PubMed Web of Science ®Google Scholar
• Linnington C, Webb M, Woodhams PL. A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody. J. Neuroimmunol.6(6), 387–396 (1984).
   PubMedGoogle Scholar
• Kuhle J, Pohl C, Mehling M et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N. Engl. J. Med.356(4), 371–378 (2007).
   PubMed Web of Science ®Google Scholar
• Lalive PH, Menge T, Delarasse C et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc. Natl Acad. Sci. USA103(7), 2280–2285 (2006).
   PubMed Web of Science ®Google Scholar
• Egg R, Reindl M, Deisenhammer F, Linington C, Berger T. Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Mult. Scler.7(5), 285–289 (2001).
   PubMed Web of Science ®Google Scholar
• Gerritse K, Deen C, Fasbender M, Ravid R, Boersma W, Claassen E. The involvement of specific anti myelin basic protein antibody-forming cells in multiple sclerosis immunopathology. J. Neuroimmunol.49(1–2), 153–159 (1994).
   PubMedGoogle Scholar
• Olsson T, Baig S, Hojeberg B, Link H. Antimyelin basic protein and antimyelin antibody-producing cells in multiple sclerosis. Ann. Neurol.27(2), 132–136 (1990).
   PubMedGoogle Scholar
• Reindl M, Linington C, Brehm U et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain122(Pt 11), 2047–2056 (1999).
   PubMed Web of Science ®Google Scholar
• Boggs JM. Myelin basic protein: a multifunctional protein. Cell. Mol. Life Sci.63(17), 1945–1961 (2006).
   PubMed Web of Science ®Google Scholar
• Wood DD, Bilbao JM, O’Connors P, Moscarello MA. Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann. Neurol.40(1), 18–24 (1996).
   PubMed Web of Science ®Google Scholar
• Musse AA, Boggs JM, Harauz G. Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope. Proc. Natl Acad. Sci. USA103(12), 4422–4427 (2006).
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology60(5), 848–853 (2003).
   PubMed Web of Science ®Google Scholar
• Misu T, Fujihara K, Nakashima I et al. Pure optic-spinal form of multiple sclerosis in Japan. Brain125(Pt 11), 2460–2468 (2002).
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med.202(4), 473–477 (2005).
   PubMed Web of Science ®Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet364(9451), 2106–2112 (2004).
   PubMed Web of Science ®Google Scholar
• Warren KG, Catz I. Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid. J. Neurol. Sci.121(1), 66–73 (1994).
   PubMed Web of Science ®Google Scholar
• Baig S, Olsson T, Yu-Ping J, Hojeberg B, Cruz M, Link H. Multiple sclerosis: cells secreting antibodies against myelin-associated glycoprotein are present in cerebrospinal fluid. Scand. J. Immunol.33(1), 73–79 (1991).
   PubMedGoogle Scholar
• Walsh MJ, Murray JM. Dual implication of 2´,3´-cyclic nucleotide 3´ phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis. J. Clin. Invest.101(9), 1923–1931 (1998).
   PubMed Web of Science ®Google Scholar
• Eikelenboom MJ, Petzold A, Lazeron RH et al. Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology60(2), 219–223 (2003).
   PubMed Web of Science ®Google Scholar
• Williamson RA, Burgoon MP, Owens GP et al. Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proc. Natl Acad. Sci. USA98(4), 1793–1798 (2001).
   PubMedGoogle Scholar
• Menge T, Lalive PH, von Budingen HC, Cree B, Hauser SL, Genain CP. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J. Allergy Clin. Immunol.116(2), 453–459 (2005).
   PubMedGoogle Scholar
• Hansen K, Cruz M, Link H. Oligoclonal Borrelia burgdorferi-specific IgG antibodies in cerebrospinal fluid in Lyme neuroborreliosis. J. Infect. Dis.161(6), 1194–1202 (1990).
   PubMed Web of Science ®Google Scholar
• Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat. Rev. Immunol.6(3), 231–243 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou D, Srivastava R, Nessler S et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc. Natl Acad. Sci. USA103(50), 19057–19062 (2006).
   PubMed Web of Science ®Google Scholar
• Marta CB, Oliver AR, Sweet RA, Pfeiffer SE, Ruddle NH. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc. Natl Acad. Sci. USA102(39), 13992–13997 (2005).
   PubMedGoogle Scholar
• Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med.5(2), 170–175 (1999).
   PubMed Web of Science ®Google Scholar
• Raine CS, Cannella B, Hauser SL, Genain CP. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann. Neurol.46(2), 144–160 (1999).
   PubMed Web of Science ®Google Scholar
• Schluesener HJ, Sobel RA, Linington C, Weiner HL. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J. Immunol.139(12), 4016–4021 (1987).
   PubMedGoogle Scholar
• Lyons JA, Ramsbottom MJ, Cross AH. Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein. Eur. J. Immunol.32(7), 1905–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Genain CP, Nguyen MH, Letvin NL et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J. Clin. Invest.96(6), 2966–2974 (1995).
   PubMedGoogle Scholar
• Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann. Neurol.43(4), 465–471 (1998).
   PubMed Web of Science ®Google Scholar
• Piddlesden SJ, Lassmann H, Zimprich F, Morgan BP, Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am. J. Pathol.143(2), 555–564 (1993).
   PubMed Web of Science ®Google Scholar
• Marta CB, Taylor CM, Coetzee T et al. Antibody cross-linking of myelin oligodendrocyte glycoprotein leads to its rapid repartitioning into detergent-insoluble fractions, and altered protein phosphorylation and cell morphology. J. Neurosci.23(13), 5461–5471 (2003).
   PubMedGoogle Scholar
• Mithen FA, Agrawal HC, Fishman MA, Eylar EH, Bunge RP. Studies with antisera against peripheral nervous system myelin and myelin basic proteins. II. Immunohistochemical studies in cultures of rat dorsal root ganglion neurons and Schwann cells. Brain Res.250(2), 333–343 (1982).
   PubMedGoogle Scholar
• Mithen FA, Agrawal HC, Eylar EH, Fishman MA, Blank W, Bunge RP. Studies with antisera against peripheral nervous system myelin and myelin basic proteins. I. Effects of antiserum upon living cultures of nervous tissue. Brain Res.250(2), 321–331 (1982).
   PubMedGoogle Scholar
• Robbie-Ryan M, Tanzola MB, Secor VH, Brown MA. Cutting edge: both activating and inhibitory Fc receptors expressed on mast cells regulate experimental allergic encephalomyelitis disease severity. J. Immunol.170(4), 1630–1634 (2003).
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Mandler RN, McGavern D et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain125(Pt 7), 1450–1461 (2002).
   PubMed Web of Science ®Google Scholar
• Keegan M, Konig F, McClelland R et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet366(9485), 579–582 (2005).
   PubMed Web of Science ®Google Scholar
• Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology64(7), 1270–1272 (2005).
   PubMed Web of Science ®Google Scholar
• Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J. Exp. Med.197(9), 1073–1081 (2003).
   PubMed Web of Science ®Google Scholar
• Litzenburger T, Fassler R, Bauer J et al. B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice. J. Exp. Med.188(1), 169–180 (1998).
   PubMedGoogle Scholar
• Krishnamoorthy G, Lassmann H, Wekerle H, Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J. Clin. Invest.116(9), 2385–2392 (2006).
   PubMed Web of Science ®Google Scholar
• Bettelli E, Baeten D, Jager A, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J. Clin. Invest.116(9), 2393–2402 (2006).
   PubMed Web of Science ®Google Scholar
• Qin Y, Duquette P, Zhang Y et al. Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis. Lab. Invest.83(7), 1081–1088 (2003).
   PubMed Web of Science ®Google Scholar
• Owens GP, Ritchie AM, Burgoon MP, Williamson RA, Corboy JR, Gilden DH. Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J. Immunol.171(5), 2725–2733 (2003).
   PubMed Web of Science ®Google Scholar
• Esiri MM. Immunoglobulin-containing cells in multiple-sclerosis plaques. Lancet2(8036), 478 (1977).
   PubMed Web of Science ®Google Scholar
• Ritchie AM, Gilden DH, Williamson RA et al. Comparative analysis of the CD19+ and CD138+ cell antibody repertoires in the cerebrospinal fluid of patients with multiple sclerosis. J. Immunol.173(1), 649–656 (2004).
   PubMed Web of Science ®Google Scholar
• Corcione A, Casazza S, Ferretti E et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl Acad. Sci. USA101(30), 11064–11069 (2004).
   PubMed Web of Science ®Google Scholar
• Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol.14(2), 164–174 (2004).
   PubMed Web of Science ®Google Scholar
• Kim HJ, Krenn V, Steinhauser G, Berek C. Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. J. Immunol.162(5), 3053–3062 (1999).
   PubMed Web of Science ®Google Scholar
• Cepok S, Rosche B, Grummel V et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain128(Pt 7), 1667–1676 (2005).
   PubMed Web of Science ®Google Scholar
• Odendahl M, Mei H, Hoyer BF et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood105(4), 1614–1621 (2005).
   PubMed Web of Science ®Google Scholar
• O’Connor BP, Raman VS, Erickson LD et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med.199(1), 91–98 (2004).
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Theil D, Derfuss T et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med.201(2), 195–200 (2005).
   PubMed Web of Science ®Google Scholar
• Cassese G, Arce S, Hauser AE et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J. Immunol.171(4), 1684–1690 (2003).
   PubMed Web of Science ®Google Scholar
• Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol.180(1–2), 63–70 (2006).
   PubMed Web of Science ®Google Scholar
• Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch. Neurol.62(2), 258–264 (2005).
   PubMed Web of Science ®Google Scholar
• Streilein JW, Niederkorn JY, Shadduck JA. Systemic immune unresponsiveness induced in adult mice by anterior chamber presentation of minor histocompatibility antigens. J. Exp. Med.152(4), 1121–1125 (1980).
   PubMed Web of Science ®Google Scholar
• Ksander BR, Streilein JW. Failure of infiltrating precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites. J. Immunol.145(7), 2057–2063 (1990).
   PubMed Web of Science ®Google Scholar
• Niederkorn JY, Streilein JW. Analysis of antibody production induced by allogeneic tumor cells inoculated into the anterior chamber of the eye. Transplantation33(6), 573–577 (1982).
   PubMed Web of Science ®Google Scholar
• Harling-Berg CJ, Knopf PM, Cserr HF. Myelin basic protein infused into cerebrospinal fluid suppresses experimental autoimmune encephalomyelitis. J. Neuroimmunol.35(1–3), 45–51 (1991).
   PubMedGoogle Scholar
• Knopf PM, Harling-Berg CJ, Cserr HF et al. Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. J. Immunol.161(2), 692–701 (1998).
   PubMed Web of Science ®Google Scholar
• Hatterer E, Davoust N, Didier-Bazes M et al. How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood107(2), 806–812 (2006).
   PubMed Web of Science ®Google Scholar
• Harling-Berg C, Knopf PM, Merriam J, Cserr HF. Role of cervical lymph nodes in the systemic humoral immune response to human serum albumin microinfused into rat cerebrospinal fluid. J. Neuroimmunol.25(2–3), 185–193 (1989).
   PubMedGoogle Scholar
• Wolf SD, Dittel BN, Hardardottir F, Janeway CA Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med.184(6), 2271–2278 (1996).
   PubMed Web of Science ®Google Scholar
• Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol.3(10), 944–950 (2002).
   PubMed Web of Science ®Google Scholar
• Kennedy MK, Torrance DS, Picha KS, Mohler KM. Analysis of cytokine mRNA expression in the CNS of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol.149(7), 2496–2505 (1992).
   PubMed Web of Science ®Google Scholar
• Bettelli E, Das MP, Howard ED, Weiner HL, Sobel RA, Kuchroo VK. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J. Immunol.161(7), 3299–3306 (1998).
   PubMed Web of Science ®Google Scholar
• Perrella O, Sbreglia C, Perrella M et al. Interleukin-10 and tumor necrosis factor-α: model of immunomodulation in multiple sclerosis. Neurol. Res.28(2), 193–195 (2006).
   PubMed Web of Science ®Google Scholar
• Navikas V, Link J, Palasik W et al. Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. Scand. J. Immunol.41(2), 171–178 (1995).
   PubMedGoogle Scholar
• Rudick RA, Ransohoff RM, Peppler R, VanderBrug Medendorp S, Lehmann P, Alam J. Interferon β induces interleukin-10 expression: relevance to multiple sclerosis. Ann. Neurol.40(4), 618–627 (1996).
   PubMed Web of Science ®Google Scholar
• Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. J. Exp. Med.197(4), 489–501 (2003).
   PubMed Web of Science ®Google Scholar
• Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity16(2), 219–230 (2002).
   PubMed Web of Science ®Google Scholar
• Stockinger B, Zal T, Zal A, Gray D. B cells solicit their own help from T cells. J. Exp. Med.183(3), 891–899 (1996).
   PubMedGoogle Scholar
• Macaulay AE, DeKruyff RH, Goodnow CC, Umetsu DT. Antigen-specific B cells preferentially induce CD4+ T cells to produce IL-4. J. Immunol.158(9), 4171–4179 (1997).
   PubMed Web of Science ®Google Scholar
• Skok J, Poudrier J, Gray D. Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development. J. Immunol.163(8), 4284–4291 (1999).
   PubMed Web of Science ®Google Scholar
• Harris DP, Haynes L, Sayles PC et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol.1(6), 475–482 (2000).
   PubMed Web of Science ®Google Scholar
• Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser M. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J. Exp. Med.192(4), 475–482 (2000).
   PubMed Web of Science ®Google Scholar
• Segal BM, Dwyer BK, Shevach EM. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med.187(4), 537–546 (1998).
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol.39(3), 285–294 (1996).
   PubMed Web of Science ®Google Scholar
• Wang X, Chen M, Wandinger KP, Williams G, Dhib-Jalbut S. IFN-β-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-β-1b therapeutic effects in multiple sclerosis. J. Immunol.165(1), 548–557 (2000).
   PubMedGoogle Scholar
• Tuohy VK, Yu M, Yin L, Mathisen PM, Johnson JM, Kawczak JA. Modulation of the IL-10/IL-12 cytokine circuit by interferon-β inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis. J. Neuroimmunol.111(1–2), 55–63 (2000).
   PubMedGoogle Scholar
• Sun CM, Deriaud E, Leclerc C, Lo-Man R. Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. Immunity22(4), 467–477 (2005).
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature441(7090), 235–238 (2006).
   PubMed Web of Science ®Google Scholar
• Cua DJ, Hutchins B, LaFace DM, Stohlman SA, Coffman RL. Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. J. Immunol.166(1), 602–608 (2001).
   PubMed Web of Science ®Google Scholar
• D’Amico G, Frascaroli G, Bianchi G et al. Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys. Nat. Immunol.1(5), 387–391 (2000).
   PubMed Web of Science ®Google Scholar
• Cumberbatch M, Dearman RJ, Kimber I. Langerhans cells require signals from both tumour necrosis factor-α and interleukin-1 β for migration. Immunology92(3), 388–395 (1997).
   Google Scholar
• Strle K, Zhou JH, Shen WH et al. Interleukin-10 in the brain. Crit. Rev. Immunol.21(5), 427–449 (2001).
   PubMed Web of Science ®Google Scholar
• MacPhee IA, Antoni FA, Mason DW. Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids. J. Exp. Med.169(2), 431–445 (1989).
   PubMed Web of Science ®Google Scholar
• Kumar V, Sercarz E. An integrative model of regulation centered on recognition of TCR peptide/MHC complexes. Immunol. Rev.182, 113–421 (2001).
   PubMed Web of Science ®Google Scholar
• McGeachy MJ, Stephens LA, Anderton SM. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J. Immunol.175(5), 3025–3032 (2005).
   PubMed Web of Science ®Google Scholar
• Ponomarev ED, Dittel BN. γδ T cells regulate the extent and duration of inflammation in the central nervous system by a Fas ligand-dependent mechanism. J. Immunol.174(8), 4678–4687 (2005).
   PubMedGoogle Scholar
• Mann MK, Maresz K, Shriver LP, Tan Y, Dittel BN. B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J. Immunol.178(6), 3447–3456 (2007).
   PubMed Web of Science ®Google Scholar
• Wei B, Velazquez P, Turovskaya O et al. Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets. Proc. Natl Acad. Sci. USA102(6), 2010–2015 (2005).
   PubMed Web of Science ®Google Scholar
• Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol.3(11), 879–889 (2003).
   PubMed Web of Science ®Google Scholar
• D’Orazio TJ, Niederkorn JY. Splenic B cells are required for tolerogenic antigen presentation in the induction of anterior chamber-associated immune deviation (ACAID). Immunology95(1), 47–55 (1998).
   PubMed Web of Science ®Google Scholar
• D’Orazio TJ, Mayhew E, Niederkorn JY. Ocular immune privilege promoted by the presentation of peptide on tolerogenic B cells in the spleen. II. Evidence for presentation by Qa-1. J. Immunol.166(1), 26–32 (2001).
   PubMedGoogle Scholar
• Hara Y, Okamoto S, Rouse B, Streilein JW. Evidence that peritoneal exudate cells cultured with eye-derived fluids are the proximate antigen-presenting cells in immune deviation of the ocular type. J. Immunol.151(10), 5162–5171 (1993).
   PubMed Web of Science ®Google Scholar
• Skelsey ME, Mayhew E, Niederkorn JY. Splenic B cells act as antigen presenting cells for the induction of anterior chamber-associated immune deviation. Invest. Ophthalmol. Vis. Sci.44(12), 5242–5251 (2003).
   PubMedGoogle Scholar
• Ashour HM, Niederkorn JY. Peripheral tolerance via the anterior chamber of the eye: role of B cells in MHC class I and II antigen presentation. J. Immunol.176(10), 5950–5957 (2006).
   PubMedGoogle Scholar
• Lanzavecchia A. Antigen uptake and accumulation in antigen-specific B cells. Immunol. Rev.99, 39–51 (1987).
   PubMed Web of Science ®Google Scholar
• Parish CR, Liew FY. Immune response to chemically modified flagellin. 3. Enhanced cell-mediated immunity during high and low zone antibody tolerance to flagellin. J. Exp. Med.135(2), 298–311 (1972).
   PubMed Web of Science ®Google Scholar
• Finkelman FD, Snapper CM, Mountz JD, Katona IM. Polyclonal activation of the murine immune system by a goat antibody to mouse IgD. IX. Induction of a polyclonal IgE response. J. Immunol.138(9), 2826–2830 (1987).
   PubMed Web of Science ®Google Scholar
• Macaulay AE, DeKruyff RH, Umetsu DT. Antigen-primed T cells from B cell-deficient JHD mice fail to provide B cell help. J. Immunol.160(4), 1694–1700 (1998).
   PubMedGoogle Scholar
• Metlay JP, Pure E, Steinman RM. Distinct features of dendritic cells and anti-Ig activated B cells as stimulators of the primary mixed leukocyte reaction. J. Exp. Med.169(1), 239–254 (1989).
   PubMedGoogle Scholar
• Lassila O, Vainio O, Matzinger P. Can B cells turn on virgin T cells? Nature334(6179), 253–255 (1988).
   PubMed Web of Science ®Google Scholar
• Eynon EE, Parker DC. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J. Exp. Med.175(1), 131–138 (1992).
   PubMed Web of Science ®Google Scholar
• Day MJ, Tse AG, Puklavec M, Simmonds SJ, Mason DW. Targeting autoantigen to B cells prevents the induction of a cell-mediated autoimmune disease in rats. J. Exp. Med.175(3), 655–659 (1992).
   PubMed Web of Science ®Google Scholar
• Saoudi A, Simmonds S, Huitinga I, Mason D. Prevention of experimental allergic encephalomyelitis in rats by targeting autoantigen to B cells: evidence that the protective mechanism depends on changes in the cytokine response and migratory properties of the autoantigen-specific T cells. J. Exp. Med.182(2), 335–344 (1995).
   PubMed Web of Science ®Google Scholar
• Chen C, Rivera A, Ron N, Dougherty JP, Ron Y. A gene therapy approach for treating T-cell-mediated autoimmune diseases. Blood97(4), 886–894 (2001).
   PubMed Web of Science ®Google Scholar
• Chen CC, Rivera A, Dougherty JP, Ron Y. Complete protection from relapsing experimental autoimmune encephalomyelitis induced by syngeneic B cells expressing the autoantigen. Blood103(12), 4616–4618 (2004).
   PubMedGoogle Scholar
• Xu B, Scott DW. A novel retroviral gene therapy approach to inhibit specific antibody production and suppress experimental autoimmune encephalomyelitis induced by MOG and MBP. Clin. Immunol.111(1), 47–52 (2004).
   PubMed Web of Science ®Google Scholar
• Soukhareva N, Jiang Y, Scott DW. Treatment of diabetes in NOD mice by gene transfer of Ig-fusion proteins into B cells: role of T regulatory cells. Cell. Immunol.240(1), 41–46 (2006).
   Google Scholar
• Primary immunodeficiency diseases. Report of a WHO scientific group. Clin. Exp. Immunol.109(Suppl. 1), 1–28 (1997).
   PubMedGoogle Scholar
• Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin. Immunol.92(1), 34–48 (1999).
   PubMed Web of Science ®Google Scholar
• Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med.345(10), 747–755 (2001).
   PubMed Web of Science ®Google Scholar
• Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet341(8848), 789–790 (1993).
   PubMed Web of Science ®Google Scholar
• Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet349(9052), 589–593 (1997).
   PubMed Web of Science ®Google Scholar
• Achiron A, Gabbay U, Gilad R et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology50(2), 398–402 (1998).
   PubMed Web of Science ®Google Scholar
• Achiron A, Kishner I, Sarova-Pinhas I et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch. Neurol.61(10), 1515–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Hommes OR, Sorensen PS, Fazekas F et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet364(9440), 1149–1156 (2004).
   PubMed Web of Science ®Google Scholar
• Reske D, Schoppe S, Broicher C, Petereit HF. The immunomodulatory properties of in vitro immunoglobulins are dose-dependent. Acta Neurol. Scand.108(4), 267–273 (2003).
   PubMedGoogle Scholar
• Aktas O, Waiczies S, Grieger U, Wendling U, Zschenderlein R, Zipp F. Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis. J. Neuroimmunol.114(1–2), 160–167 (2001).
   PubMed Web of Science ®Google Scholar
• Durelli L, Isoardo G. High-dose intravenous immunoglobulin treatment of multiple sclerosis. Neurol. Sci.23(Suppl. 1), S39–S48 (2002).
   Google Scholar
• Sorensen PS, Wanscher B, Jensen CV et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology50(5), 1273–1281 (1998).
   PubMed Web of Science ®Google Scholar
• Jorgensen SH, Storm N, Jensen PE, Laursen H, Sorensen PS. IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions. Exp. Brain Res.178(4), 462–469 (2006).
   PubMedGoogle Scholar
• Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol. Rev.110, 135–149 (1989).
   PubMed Web of Science ®Google Scholar
• Stangel M, Compston A, Scolding NJ. Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins (“IVIg”). J. Neuroimmunol.103(2), 195–201 (2000).
   PubMed Web of Science ®Google Scholar
• Janke AD, Giuliani F, Yong VW. IVIg attenuates T cell-mediated killing of human neurons. J. Neuroimmunol.177(1–2), 181–188 (2006).
   PubMedGoogle Scholar
• Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho ES. Multiple sclerosis: remyelination of nascent lesions. Ann. Neurol.33(2), 137–151 (1993).
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Lennon VA, Benveniste EN, Merrill JE. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. J. Neuropathol. Exp. Neurol.46(1), 84–95 (1987).
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Lennon VA. Immunoglobulins promote remyelination in the central nervous system. Ann. Neurol.27(1), 12–17 (1990).
   PubMed Web of Science ®Google Scholar
• Asakura K, Miller DJ, Pease LR, Rodriguez M. Targeting of IgMk antibodies to oligodendrocytes promotes CNS remyelination. J. Neurosci.18(19), 7700–7708 (1998).
   PubMed Web of Science ®Google Scholar
• Bieber AJ, Warrington A, Pease LR, Rodriguez M. Humoral autoimmunity as a mediator of CNS repair. Trends Neurosci.24(11 Suppl.), S39–S44 (2001).
   PubMedGoogle Scholar
• Bansal R, Pfeiffer SE. Reversible inhibition of oligodendrocyte progenitor differentiation by a monoclonal antibody against surface galactolipids. Proc. Natl Acad. Sci. USA86(16), 6181–6185 (1989).
   PubMed Web of Science ®Google Scholar
• Rosenbluth J, Liu Z, Guo D, Schiff R. Inhibition of CNS myelin development in vivo by implantation of anti-GalC hybridoma cells. J. Neurocytol.23(11), 699–707 (1994).
   PubMedGoogle Scholar
• Nakahara J, Tan-Takeuchi K, Seiwa C et al. Signaling via immunoglobulin Fc receptors induces oligodendrocyte precursor cell differentiation. Dev. Cell4(6), 841–852 (2003).
   PubMed Web of Science ®Google Scholar
• Keirstead HS, Blakemore WF. Identification of post-mitotic oligodendrocytes incapable of remyelination within the demyelinated adult spinal cord. J. Neuropathol. Exp. Neurol.56(11), 1191–1201 (1997).
   PubMed Web of Science ®Google Scholar
• Chang A, Tourtellotte WW, Rudick R, Trapp BD. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med.346(3), 165–173 (2002).
   PubMed Web of Science ®Google Scholar